Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

NCT05412004 on ClinicalTrials.gov · last registry update 2025-04-30

Finished 12 March 2024, after enrolling 469 people. Primary outcome, as filed: Change From Baseline in Apnea-Hypopnea Index (AHI). tirzepatide is already approved in the US for obesity and sleep apnea, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 469
Started: 2022-06-21
Primary completion: 2024-03-12 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Apnea-Hypopnea Index (AHI)

Conditions studied

Obstructive Sleep Apnea · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.